RhumbLine Advisers
KYMR icon

RhumbLine Advisers’s Kymera Therapeutics KYMR Stock Holding History

RhumbLine Advisers’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.25M Buy
80,684
+9,006
+13% +$774K 0.01% 1139
2026
Q1 		$5.97M Sell
71,678
-626
-0.9% -$49.6K 0.01% 1310
2025
Q4 		$5.63M Sell
72,304
-1,869
-3% -$126K ﹤0.01% 1340
2025
Q3 		$4.2M Buy
74,173
+3,115
+4% +$140K ﹤0.01% 1528
2025
Q2 		$3.1M Buy
71,058
+1,130
+2% +$38.9K ﹤0.01% 1654
2025
Q1 		$1.91M Buy
69,928
+5,771
+9% +$210K ﹤0.01% 1827
2024
Q4 		$2.58M Buy
64,157
+1,861
+3% +$84.1K ﹤0.01% 1748
2024
Q3 		$2.95M Sell
62,296
-2,239
-3% -$98.9K ﹤0.01% 1688
2024
Q2 		$1.93M Buy
64,535
+7,143
+12% +$247K ﹤0.01% 1908
2024
Q1 		$2.31M Buy
57,392
+3,889
+7% +$139K ﹤0.01% 1837
2023
Q4 		$1.36M Sell
53,503
-124
-0.2% -$2.22K ﹤0.01% 2102
2023
Q3 		$745K Sell
53,627
-17
-0% -$342 ﹤0.01% 2370
2023
Q2 		$1.23M Sell
53,644
-10,283
-16% -$295K ﹤0.01% 2179
2023
Q1 		$1.89M Buy
63,927
+2,707
+4% +$87.3K ﹤0.01% 1835
2022
Q4 		$1.53M Buy
61,220
+993
+2% +$26.5K ﹤0.01% 1927
2022
Q3 		$1.31M Buy
60,227
+5,339
+10% +$141K ﹤0.01% 1999
2022
Q2 		$1.08M Buy
54,888
+18,680
+52% +$436K ﹤0.01% 2102
2022
Q1 		$1.53M Buy
36,208
+2,481
+7% +$105K ﹤0.01% 1937
2021
Q4 		$2.14M Buy
33,727
+474
+1% +$27.6K ﹤0.01% 1841
2021
Q3 		$1.95M Buy
33,253
+5,696
+21% +$330K ﹤0.01% 1919
2021
Q2 		$1.34M Buy
27,557
+16,141
+141% +$701K ﹤0.01% 2121
2021
Q1 		$444K Buy
11,416
+925
+9% +$55.7K ﹤0.01% 2546
2020
Q4 		$650K Buy
+10,491
New +$512K ﹤0.01% 2328

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

RhumbLine Advisers's KYMR Position: Q2 2026 in Review

RhumbLine Advisers increased its Kymera Therapeutics (KYMR) stake by 13% in Q2 2026, buying an estimated $774K and bringing the position to 80,684 shares worth $9.25M. The position accounts for 0.01% of the portfolio, ranked #1139.

RhumbLine Advisers first reported a position in KYMR in Q4 2020 and has held it in 23 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • RhumbLine Advisers held 80,684 shares of Kymera Therapeutics worth $9.25M as of Q2 2026.
  • RhumbLine Advisers bought 9,006 Kymera Therapeutics shares in Q2 2026, an estimated $774K.
  • Kymera Therapeutics made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1139 holding.
  • RhumbLine Advisers first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.